DRUG ICT-107-301-STING (Study of Immunotherapy in Newly Diagnosed Glioblastoma): A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ c

Project: Research project

Project Details

StatusFinished
Effective start/end date12/1/16 → 12/1/19

Funding

  • Novella Clinical, LLC (Prot# ICT-107-301)
  • ImmunoCellular Therapeutics, Ltd. (Prot# ICT-107-301)